Pol­i­tics, pric­ing con­tro­ver­sy, tax re­form and steep val­u­a­tions con­spire to con­fuse Sanofi’s M&A strat­e­gy

One of the big ques­tions fac­ing the in­dus­try right now is whether or not the M&A train will get rolling in a mean­ing­ful way in 2017. It’s clear that many of the ma­jor play­ers — the ones ex­pect­ed to add bil­lions in meaty deals to the bare bones of what we’ve been see­ing — have been caught at least some­what off bal­ance by a new pres­i­dent that con­stant­ly spouts off about out­ra­geous­ly high drug costs as well as plans to re­form cor­po­rate tax­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.